Web1 day ago · The Mosaic Therapeutics team at Wellcome Genome Campus. Picture: J.Britton. The company’s targeted oncology therapies have been spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute. The investment was raised from Syncona Investment Management and Cambridge Innovation … WebApr 11, 2024 · CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2024 financial results and business updates on Wednesday, May 3, 2024, before the U.S. financial …
Bicycle Therapeutics plc: Bicycle Therapeutics to Present at the …
WebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today … WebSEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the images of the milky way at night
Akebia Therapeutics to Host Stockholder Information Session to …
WebThese proprietary technologies formed the foundation in 2010 of Kymab Ltd. Kymab was conceived as a platform-to-product company, where the first few years were focused on … WebFunding of up to £20,000 is available for projects in the remit of the Future of Therapeutics which progress translational interdisciplinary work in the priority areas of Wellcome: … WebSanger spin-out Mosaic Therapeutics shows strength of Institute’s cancer research ... Cambridge Innovation Capital invests in Mosaic Therapeutics $28m Series A Funding ... 🟣 CAR T-cell therapy has exhibited conspicuous clinical efficacy in hematological malignancies, but more than half of patients will relapse. images of the month of february